Aims: Short-term intensive insulin therapy induces long-term drug-free euglycemic remission in half of patients with newly diagnosed type 2 diabetes mellitus (T2DM) but causes an increased risk of hypoglycemia. Studies identifying the impact of hypoglycemia are necessary.

Methods: We analyzed data from three randomized prospective trials conducted at our institution from 2002 to 2015. A continuous subcutaneous insulin infusion (CSII) was provided to achieve the glycemic goals and then maintained for 14 days.

Results: Patients who attained one-year drug-free glycemic remission were younger (48.06±9.85 vs. 50.95±11.70 years, P=0.037) and had a higher body mass index (BMI) (25.53±3.52 vs. 24.66±3.20 kg/m2, P=0.046) than those who did not. Notably, the median number of episodes of mild hypoglycemia with nadir glucose values of 3.0-3.9 mmol/L was higher in the remission group than in the non-remission group (5 (6) vs. 2 (5), P<0.001). However, the number of episodes of clinically significant hypoglycemia (<3.0 mmol/L) was insignificantly lower in the remission group (0 (1) vs. 0 (1), P=0.273). Patients with higher glucose levels (glycated hemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial glucose (PPG)) and lower ?-cell functions (homeostasis model assessment of ?-cell function (HOMA-B)) at baseline faced a greater risk of clinically significant hypoglycemia (OR=2.02, 95% CI 1.40-2.92, P<0.001). According to the logistic regression analysis, mild hypoglycemic episodes were positively and independently related to long-term glycemic remission.

Conclusions: Mild hypoglycemic episodes during CSII therapy are related to better long-term drug-free glycemic remission in patients with newly diagnosed T2DM. However, clinically significant hypoglycemia is not correlated and should be avoided.


L. Xu: None. Y. Li: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at